We are a national medical device distribution company.
We build partnerships with suppliers, organizing and developing their sales & marketing.
We serve as a reference for healthcare by offering reliable and innovative treatment solutions.
The experience we have gained through many years in the medical device distribution sector allows us to offer a wide range of quality solutions for cardiovascular, dialysis, infusion and intensive care therapy.
We offer specialized devices for cardiac surgery, interventional cardiology, radiology and vascular intervention.
FIELD OF BLOOD
We offer solutions for hemodialysis, laboratory pre-analytics, transfusion.
INTENSIVE CARE, INFUSION MANAGEMENT AND NEUROMODULATION
We distribute a wide range of innovative and quality products for use in the various areas of infusion management and of intensive care: from resuscitation to intensive care therapies, from general surgery to neuromodulation, from point of care testing to devices for the preparation and injection of
A UNIQUE MODEL OF QUALITY
Gada Italia has reinvented the traditional relationship between supplier and distributor with the creation of a distinctive Business Model, characterized by the organization of sales & marketing and processes for defining objectives and ways to achieve them.
This Unique Model is based on constant dialogue with supplying partners in order to strengthen the relationship, making it collaborative, transparent and long-term.
The company is certified UNI EN ISO 14001:2015 in regards to environmental management systems and UNI ES ISO 9001:2015 in regards to quality management systems.
Since 1978 we have been working with commitment and passion to distribute cutting-edge medical technologies for health care. In over 40 years we have become the reference point for public and private hospitals, clinics, university centers and purchasing groups.
THE LATEST NEWS
Imperial College London magazine announces that Dr Ranil De Silva (Royal Brompton and Harefield Hospitals, UK) with the support of the British Heart Foundation will conduct a study, the REMEDY-PILOT, to
The Journal of Invasive Cardiology (J INVASIVE CARDIOL 2019;31:52-56) publishes a prospective, non-randomized study about the safety and efficacy of elective use of hemodynamic support by the Impella
Neovasc, partner of GADA and leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices